UCB PHARMA SA

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Public, Subsidiary

Established: 1928-01-01

Employees: 9K

Market Cap: $34.9B

Website: https://www.ucb-iberia.com/home

Clinical Trials

Wheal and Flare Reaction During 24 Hours in Allergic Volunteers.

Phase 1

Completed

Conditions: Allergy

First Posted Date: 2007-08-27

Last Posted Date: 2013-12-16

Lead Sponsor: UCB Pharma

Registration Number: NCT00521170

Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children

Phase 2

Completed

Conditions: Cough

First Posted Date: 2007-08-27

Last Posted Date: 2013-12-12

Lead Sponsor: UCB Pharma

Target Recruit Count: 15

Registration Number: NCT00520754

Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR

Not Applicable

Completed

Conditions: Rhinitis, Allergic, Seasonal

First Posted Date: 2007-08-27

Last Posted Date: 2013-12-12

Lead Sponsor: UCB Pharma

Target Recruit Count: 459

Registration Number: NCT00521040

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Phase 3

Terminated

Conditions: Parkinson's Disease

Interventions: Drug: Rotigotine

First Posted Date: 2007-08-22

Last Posted Date: 2014-10-27

Lead Sponsor: UCB Pharma

Target Recruit Count: 84

Registration Number: NCT00519532

Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Lacosamide

First Posted Date: 2007-08-14

Last Posted Date: 2017-08-28

Lead Sponsor: UCB Pharma

Target Recruit Count: 376

Registration Number: NCT00515619

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

Phase 2

Completed

Conditions: Epilepsy

Interventions: Drug: Levetiracetam

First Posted Date: 2007-07-25

Last Posted Date: 2015-07-15

Lead Sponsor: UCB Pharma SA

Target Recruit Count: 19

Registration Number: NCT00505934

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Phase 3

Completed

Conditions: Idiopathic Parkinson's Disease

Interventions: Drug: Rotigotine

First Posted Date: 2007-07-23

Last Posted Date: 2014-10-02

Lead Sponsor: UCB Pharma

Target Recruit Count: 186

Registration Number: NCT00505687

Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Placebo
Drug: Brivaracetam

First Posted Date: 2007-07-20

Last Posted Date: 2018-04-03

Lead Sponsor: UCB Pharma SA

Target Recruit Count: 480

Registration Number: NCT00504881

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease

Phase 3

Completed

Conditions: Advanced Stage Parkinson's Disease

Interventions: Drug: Rotigotine

First Posted Date: 2007-07-17

Last Posted Date: 2014-10-02

Lead Sponsor: UCB Pharma

Target Recruit Count: 395

Registration Number: NCT00501969

Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects

Phase 3

Completed

Conditions: Idiopathic Restless Legs Syndrome

First Posted Date: 2007-07-09

Last Posted Date: 2014-09-25

Lead Sponsor: UCB Pharma

Target Recruit Count: 341

Registration Number: NCT00498108

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy